The funding round was led by Oxford Science Enterprises to support growth in the US and UK markets.
"We invest in companies with the potential to become leaders in their field, and that is why we’re proud to back the incredible team at Navenio on their latest fundraise. Navenio is revolutionising the way we create more efficient healthcare workplaces, through its proven technology powered platform for indoor mapping, and we are excited to continue supporting the team on the next stage of the company’s journey as they look to deliver its offering to a wider range of use cases and across new geographies."
— Heather Roxborough, senior partner of Health Tech
The robotics and analytics firm has added backing from Schenker Ventures following its recent Series A raise.
"Technology that operates autonomously, provides real-time insights, possesses intuitive interfaces, and seamlessly integrates can lead to a revolutionary transformation in the day-to-day efficiency, productivity and precision of warehouse operations"
The financing was co-led by Illumina Ventures and Mérieux Equity Partners to support the development and commercialisation of the company gene editing safety technology.
"Our vision is a future where cell and gene therapies are safer, more efficient, and affordable for patients. Operating at the intersection of biology, bioinformatics and data science, our INDUCE-seq platform offers an unbiased, end-to-end solution that expedites the measurement and assessment of off-target gene editing during therapeutic development. This provides essential information required to progress therapeutic programs that leverage gene editing and mitigate potential risks that can result in later-stage clinical failures. By developing a deployable PaaS offering, we have the opportunity to provide the cell and gene therapy community with this much-needed solution and achieve rapid market growth."
The investment round was led by FirstPartyCapital with participation from strategic industry angels and AperiamVentures.
"We spent our first few years bootstrapping and I’m incredibly proud of that achievement. The goal with this latest round of investment is to accelerate growth, establishing ourselves in the US market to bring our user-first platform to a wider, global audience. Having FPC, AperiamVentures, Gurman Hundal, and Brian O’Kelley as part of that journey will allow us to deliver a better ad experience for both consumers and brands. And being able to do so with our continued focus on sustainability means we will strive to be a positive force on the industry."
The London-based fintech secured £19.3m to accelerate product development and expand internationally.
"In a very tough fundraising environment, this investment represents terrific confidence in what we’ve built so far and in HyperJar’s future as a global business."
